BridgeBio's Attruby Appears to Outshine Pfizer's Vyndamax in Crucial Real-World Study for ATTR-CM The Unfolding Story of Hope: BridgeBio's Double Victory in the Battle Against Rare Disease A CRISPR Conundrum: Intellia's Trial Halt Jolts the Biotech World Acoramidis: A Beacon of Hope for Rare Heart Disease Patients with Rapid Cardiac Benefit